{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:30Z","timestamp":1790009070497,"version":"4.0.1"},"reference-count":48,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:p>Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a larger number of components, while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke\u2014the so-called three-point major adverse CV event (3P-MACE) composite\u2014or add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACE may offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a \u201cgold standard\u201d for CVOTs of all glucose-lowering drugs.<\/jats:p>","DOI":"10.2337\/dc17-0068","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T15:40:15Z","timestamp":1503416415000},"page":"1144-1151","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":66,"title":["Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?"],"prefix":"10.2337","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct01243424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01897532","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nikolaus","family":"Marx","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"von Eynatten","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothis T.","family":"George","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"2022031301264169700_B1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","article-title":"Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes","volume":"383","author":"Holman","year":"2014","journal-title":"Lancet"},{"key":"2022031301264169700_B3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B4","unstructured":"U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [Internet], 2 December 2016. Silver Spring, MD, U.S. Food and Drug Administration. Available from http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm531517.htm. Accessed 15 May 2017"},{"key":"2022031301264169700_B5","unstructured":"Jardiance (empagliflozin) prescribing information [Internet], December 2016. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals, Inc., and Indianapolis IN, Eli Lilly and Company. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s008lbl.pdf. Accessed 15 May 2017"},{"key":"2022031301264169700_B6","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Jardiance (empagliflozin) [Internet], 15 December 2016 (EMA\/398392\/2016). Available from http:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500218154. Accessed 15 May 2017"},{"key":"2022031301264169700_B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"},{"key":"2022031301264169700_B10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2009.2017","article-title":"Composite end points in randomized trials: there is no free lunch","volume":"303","author":"Tomlinson","year":"2010","journal-title":"JAMA"},{"key":"2022031301264169700_B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"2022031301264169700_B12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamainternmed.2014.1803","article-title":"Decade-long trends in mortality among patients with and without diabetes mellitus at a major academic medical center","volume":"174","author":"Butala","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2022031301264169700_B13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1161\/CIRCOUTCOMES.115.001717","article-title":"Who must we target now to minimize future cardiovascular events and total mortality? Lessons from the Surveillance, Prevention and Management of Diabetes Mellitus (SUPREME-DM) cohort study","volume":"8","author":"Desai","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022031301264169700_B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2337\/dc15-2308","article-title":"Age-specific trends from 2000\u20132011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people","volume":"39","author":"Harding","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301264169700_B15","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00125-013-3063-1","article-title":"Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study","volume":"56","author":"Lind","year":"2013","journal-title":"Diabetologia"},{"key":"2022031301264169700_B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdiacomp.2007.12.002","article-title":"Reductions in excess mortality rates among people with diabetes by selected cause of death","volume":"23","author":"Tierney","year":"2009","journal-title":"J Diabetes Complications"},{"key":"2022031301264169700_B17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B18","unstructured":"Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet], December 2008. Silver Spring, MD, U.S. Food and Drug Administration. Available from http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf. Accessed 15 May 2017"},{"key":"2022031301264169700_B19","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2015.10.051","article-title":"Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022031301264169700_B20","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.2337\/dcS15-3024","article-title":"Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis","volume":"39","author":"Mannucci","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301264169700_B21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031301264169700_B22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2022031301264169700_B23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022031301264169700_B24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0002-9149(98)00226-4","article-title":"Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy)","volume":"82","author":"Holmvang","year":"1998","journal-title":"Am J Cardiol"},{"key":"2022031301264169700_B25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/euhj.1998.1351","article-title":"The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee\u2019s final decision on end-points","volume":"20","author":"N\u00e4slund","year":"1999","journal-title":"Eur Heart J"},{"key":"2022031301264169700_B26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/aje\/kwh314","article-title":"Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women\u2019s Health Initiative","volume":"160","author":"Heckbert","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2022031301264169700_B27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2022031301264169700_B28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301264169700_B29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1161\/CIRCRESAHA.116.306924","article-title":"Heart failure considerations of antihyperglycemic medications for type 2 diabetes","volume":"118","author":"Standl","year":"2016","journal-title":"Circ Res"},{"key":"2022031301264169700_B30","unstructured":"AstraZeneca. AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure [Internet], 12 September 2016. Available from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2016\/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html. Accessed 15 May 2017"},{"key":"2022031301264169700_B31","unstructured":"Boehringer Ingelheim. Jardiance (empagliflozin) to be studied for the treatment of people with chronic heart failure [Internet], 19 April 2016. Available from https:\/\/www.boehringer-ingelheim.com\/press-release\/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure. Accessed 15 May 2017"},{"key":"2022031301264169700_B32","unstructured":"Center for Biologics Evaluation and Research. Multiple endpoints in clinical trials: guidance for industry (draft guidance) [Internet], January 2017. Silver Spring, MD, U.S. Food and Drug Administration. Available from http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM536750.pdf. Accessed 15 May 2017"},{"key":"2022031301264169700_B33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMra1601511","article-title":"The primary outcome is positive\u2014is that good enough?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B34","unstructured":"Center for Drug Evaluation and Research. Meeting expectations to exclude a CV risk margin of 1.3. In Application number: 204042Orig1s000 summary review [Internet], March 2013, p. 20. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000SumR.pdf. Accessed 15 May 2017"},{"key":"2022031301264169700_B35","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2022031301264169700_B36","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Reflection paper on assessment of cardiovascular safety profile of medicinal products [Internet], 25 February 2016 (EMA\/CHMP\/50549\/2015). Available from www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500203804. Accessed 15 May 2017"},{"key":"2022031301264169700_B37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B39","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/dc08-1671","article-title":"Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial","volume":"32","author":"Raz","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301264169700_B41","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B44","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B45","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301264169700_B47","unstructured":"ClinicalTrials.gov. A study to evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650 [Internet]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01455896. Accessed 19 October 2016"},{"key":"2022031301264169700_B48","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/9\/1144\/548829\/dc170068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/9\/1144\/548829\/dc170068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:16:57Z","timestamp":1647130617000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/9\/1144\/36706\/Composite-Primary-End-Points-in-Cardiovascular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,8,14]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-0068","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]}}}